Increased hydrophobicity and estrogenic activity of simple phenols with silicon and germanium-containing substituents

Journal of Medicinal Chemistry

Volumn 56, Issue 1, 2013, Pages 160-166

  Fujii, Shinya ^a   Miyajima, Yu ^a   Masuno, Hiroyuki ^a   Kagechika, Hiroyuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON; GERMANIUM; PHENOL DERIVATIVE; SILICON; TRIMETHYLGERMYLPHENOL; TRIMETHYLSILYLPHENOL; UNCLASSIFIED DRUG;

ACIDITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SYNTHESIS; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL; HYDROPHOBICITY; STRUCTURE ACTIVITY RELATION;

BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; GENES, REPORTER; GERMANIUM; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LUCIFERASES; MOLECULAR DOCKING SIMULATION; ORGANOMETALLIC COMPOUNDS; ORGANOSILICON COMPOUNDS; PHENOLS; RADIOLIGAND ASSAY; TRANSCRIPTION, GENETIC;

EID: 84872293098     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3013757     Document Type: Article

References (42)

1. Protein-Ligand Interactions (Methods and Principles in Medicinal Chemistry); Gohlke, H., Ed.; Wiley-VCH: Weinheim, Germany, 2012.
2. The Borane, Carborane, Carbocation Continuum; Casanova, J., Ed.; Wiley Interscience: New York, 1998.
3. Carboranes, 2nd ed.; Grimes, R. N., Ed.; Academic Press: New York, 2011. For reviews of carboranes
4. 12 and their derivatives Chem. Rev. 1992, 92, 209-223
5. Soloway, A. H.; Tjarks, W.; Barnum, B. A.; Rong, F.-G.; Barth, R. F.; Codogni, I. M.; Wilson, J. G. The chemistry of neutron capture therapy Chem. Rev. 1998, 98, 1515-1562
6. Iijima, T.; Endo, Y.; Tsuji, M.; Kawachi, E.; Kagechika, H.; Shudo, K. Dicarba- closo -dodecaboranes as a pharmacophore. Retinoidal antagonists and potential agonists Chem. Pharm. Bull. 1999, 47, 398-404
7. Endo, Y.; Yaguchi, K.; Kawachi, E.; Kagechika, H. Polymethylcarborane as a novel bioactive moiety: derivatives with potent retinoid antagonistic activity Bioorg. Med. Chem. Lett. 2000, 10, 1733-1736
8. Endo, Y.; Iijima, T.; Yaguchi, K.; Kawachi, E.; Inoue, N.; Kagechika, H.; Kubo, K.; Itai, A. Structure-activity study of retinoid agonists bearing substituted dicarba- closo -dodecaborane. Relation between retinoidal activity and conformation of two aromatic nuclei Bioorg. Med. Chem. Lett. 2001, 11, 1307-1311
9. Fujii, S.; Masuno, H.; Taoda, Y.; Kano, A.; Wongmayura, A.; Nakabayashi, M.; Ito, N.; Shimizu, M.; Kawachi, E.; Hirano, T.; Endo, Y.; Tanatani, A.; Kagechika, H. Boron cluster-based development of potent nonsecosteroidal vitamin D receptor ligands: direct observation of hydrophobic interaction between protein surface and carborane J. Am. Chem. Soc. 2011, 133, 20933-20941
10. Wongmayura, A.; Fujii, S.; Ito, S.; Kano, A.; Taoda, Y.; Kawachi, E.; Kagechika, H.; Tanatani, A. Novel vitamin D receptor ligands bearing a spherical hydrophobic core structure: comparison of bicyclic hydrocarbon derivatives with boron cluster derivatives Bioorg. Med. Chem. Lett. 2012, 22, 1756-1760
11. Endo, Y.; Iijima, T.; Yamakoshi, Y.; Yamaguchi, M.; Fukasawa, H.; Shudo, K. Potent estrogenic agonists bearing dicarba- closo -dodecaborane as a hydrophobic pharmacophore J. Med. Chem. 1999, 42, 1501-1504
12. Endo, Y.; Iijima, T.; Yamakoshi, Y.; Fukasawa, H.; Miyaura, C.; Inada, M.; Kubo, A.; Itai, A. Potent agonists based on carborane as a hydrophobic skeletal structure: a new medicinal application of boron clusters Chem. Biol. 2001, 8, 341-355
13. Endo, Y.; Yoshimi, T.; Ohta, K.; Suzuki, T.; Ohta, S. Potent estrogen receptor ligands based on bisphenols with a globular hydrophobic core J. Med. Chem. 2005, 48, 3941-3944
14. Fujii, S.; Goto, T.; Ohta, K.; Hashimoto, Y.; Suzuki, T.; Ohta, S.; Endo, Y. Potent androgen antagonists based on carborane as a hydrophobic core structure J. Med. Chem. 2005, 48, 4654-4662
15. Fujii, S.; Hashimoto, Y.; Suzuki, T.; Ohta, S.; Endo, Y. A new class of androgen receptor antagonists bearing carborane in place of a steroidal skeleton Bioorg. Med. Chem. Lett. 2005, 15, 227-230
16. Fujii, S.; Ohta, K.; Goto, T.; Kagechika, H.; Endo, Y. Acidic heterocycles as novel hydrophilic pharmacophore of androgen receptor ligands with a carborane core structure Bioorg. Med. Chem. 2009, 17, 344-350
17. Fujii, S.; Yamada, A.; Tomita, K.; Nagano, M.; Goto, T.; Ohta, K.; Harayama, T.; Endo, Y.; Kagechika, H. p -Carborane-based androgen antagonists active in LNCaP cells with a mutated androgen receptor Med. Chem. Commun. 2011, 2, 877-880
18. Fujii, S.; Ohta, K.; Goto, T.; Oda, A.; Masuno, H.; Endo, Y.; Kagechika, H. Development of androgen receptor ligands by application of ten-vertex para -carborane as a novel hydrophobic core structure Med. Chem. Commun. 2012, 3, 680-684
19. Showell, G. A.; Mills, J. S. Chemistry challenges in lead optimization: silicon isosteres in drug discovery Drug Discovery Today 2003, 8, 551-556
20. Mills, J. S.; Showell, G. A. Exploitation of silicon medicinal chemistry in drug discovery Expert Opin. Investig. Drugs 2004, 13, 1149-1157
21. Gately, S.; West, R. Novel therapeutics with enhanced biological activity generated by the strategic introduction of silicon isosteres into known drug scaffolds Drug Dev. Res 2007, 68, 156-163
22. Yamakawa, T.; Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Shudo, K. Retinobenzoic acids. 5. Retinoidal activities of compounds having a trimethylsilyl or trimethylgermyl group(s) in human promyelocytic leukemia cells HL-60 J. Med. Chem. 1990, 33, 1430-1437
23. Higginbotham, K. B.; Lozano, R.; Brown, T.; Patt, Y. Z.; Arima, T.; Abbruzzese, J. L.; Thomas, M. B. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma J. Cancer Res. Clin. Oncol. 2008, 134, 1325-1335
24. Tacke, R.; Müller, V.; Buettner, M. W.; Lippert, W. P.; Bertermann, R.; Daiss, J. O.; Khanwalkar, H.; Furst, A.; Gaudon, C.; Gronemeyer, H. Synthesis and pharmacological characterization of disila-AM80 (disila-tamibarotene) and disila-AM580, silicon analogues of the RARα-selective retinoid agonists AM80 (tamibarotene) and AM580 ChemMedChem 2009, 4, 1797-1802
25. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer Van Hattum, A. H.; Pinedo, H. M.; Schluper, H. M. M.; Hausheer, F. H.; Boven, E. Int. J. Cancer 2000, 88, 260-266
26. Daud, A.; Valkov, N.; Centeno, B.; Derderian, J.; Sullivan, P.; Munster, P.; Urbas, P.; DeConti, R. C.; Berghorn, E.; Liu, Z.; Hausheer, F.; Sullivan, D. Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study Clin. Cancer Res. 2005, 11, 3009-3016
27. Munster, P. N.; Daud, A. I. Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma Expert Opin. Investig. Drugs 2011, 20, 1565-1574
28. Hansch, C.; Leo, A.; Unger, S. H.; Kim, K. H.; Nikaitani, D.; Lien, E. J. "Aromatic" substituent constants for structure-activity correlations J. Med. Chem. 1973, 16, 1207-1216
29. Katzenellenbogen, J. A. The 2010 Philip S. Portoghese Medicinal Chemistry Lectureship: Addressing the "Core Issue" in the Design of Estrogen Receptor Ligands J. Med. Chem. 2011, 54, 5271-5282
30. OECD Guideline for Testing of Chemicals 117, Partition Coefficient (n-octanol/water), High Performance Liquid Chromatography (HPLC) Method; March 1989.
31. Fujita, T.; Iwasa, J.; Hansch, C. A new substituent constant, π, derived from partition coefficients J. Am. Chem. Soc. 1964, 86, 5175-5180
32. 2H (M = C, Si, Ge, and Sn, and R = Me and Et) and the relative strengths of dπ-pπ-bonding in the M-Car bond J. Chem. Soc. 1954, 4403-4411
33. Benkeser, R. A.; Krysiak, H. R. The conjugate ability of the trimethylsilyl group J. Am. Chem. Soc. 1953, 75, 2421-2425
34. Evans, R. M. The steroid and thyroid hormone receptor superfamily Science 1988, 240, 889-894
35. McEwan, I. J. Gene regulation through chromatin remodeling by members of the nuclear receptor superfamily Biochem. Soc. Trans. 2000, 28, 369-373
36. Yamakoshi, Y.; Otani, Y.; Fujii, S.; Endo, Y. Dependence of estrogenic activity on the shape of the 4-alkyl substituent in simple phenols Biol. Pharm. Bull. 2000, 23, 259-261
37. Ohta, K.; Chiba, Y.; Ogawa, T.; Endo, Y. Promising core structure for nuclear receptor ligands: design and synthesis of novel estrogen receptor ligands based on diphenylamine skeleton Bioorg. Med. Chem. Lett. 2008, 18, 5050-5053
38. Wilson, V. S.; Bobseine, K.; Gray, L. E., Jr. Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists Toxicol. Sci. 2004, 81, 69-77
39. Carlson, K. E.; Choi, I.; Gee, A.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction Biochemistry 1997, 36, 14897-14905
40. Eiler, S.; Gangloff, M.; Duclaud, S.; Moras, D.; Ruff, M. Overexpression, purification, and crystal structure of native ER alpha LBD Protein Expression Purif. 2001, 2, 165-173
41. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity J. Comput. Chem. 2009, 16, 2785-2791
42. Bates, R. G. Determination of pH, Theory and Practice; Wiley: New York, 1973.